No Detail Found!

Association of p21waf1 CDK-interacting Protein 1 Expression on Progression Free Survival and TNM Staging in Breast Cancer Patients Using Tamoxifen Hormonal Therapy

Author(s)
Abdulameer Kareem Leelo Al-Obaidy Department of Basic Medical Science, Nursing College, Al-Qadisiyah University, Diwaniyah, Iraq
Hawraa A. Kareem Department of Al-Jawad Oncology Center, Al-Emamain Al-Kadimain Medical City, Ministry of Health of Iraq, Baghdad, Iraq
Yusra Jabbar Hasan Egyptian Board of Medical Oncology, Department of Al-Jawad Oncology Center, Al-Emamain Al-Kadimain Medical City, Baghdad, Iraq
Abstract
Objectives: Background and Aim: Examining the relationship among p21WAF1, Progression-Free Survival (PFS), TNM staging and tamoxifen treatment in hormone-sensitive breast cancer patients may yield insights into additional robust biomarkers for timely identification and prognosis of breast carcinoma. Patients and Methods: A prospective observational study was conducted including 78 female patients with breast cancer who were monitored for five years. The mean age among participants was 41.54 years and their mean weight was 75.62 kg prior to therapy. Patients receiving tamoxifen therapy were categorized into four groups based on TNM staging: T2N0M0 (30 patients), T2N1M0 (28 patients), T3N0M0 (14 patients) and the last group T4N1M0 (6 patients). Results: All patients are hormone receptor-positive and exhibited varying degrees of p21Waf1 expression, with nuclear p21 expression percentages ranging from 25% to less than 85%. The statistical analysis revealed a substantial reduction in p21Waf1 expression associated with increased tumor growth and lymphatic metastasis (TNM), with p<0.005. The influence of TNM staging in conjunction with p21Waf1 expression on Progression-Free Survival (PFS) duration indicates that patients classified as T3N0M0 have the shortest PFS, whereas an increased PFS is noted in T2N1M0, with further enhancement in T4N1M0 and T2N0M0 stages. Patient age and weight prior to treatment significantly impact Progression-Free Survival (PFS) in stages T2N0M0 and T2N1M0 more than in stages T3N0M0 and T4N1M0. Conclusion: The findings indicate that p21Waf1 is a crucial regulator of tumor response to tamoxifen and enhancing p21Waf1 levels may be effective in addressing acquired resistance.
Publication Details
Page(s) 90-99
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 8, Year: 2025

Request the full text from PASTIC

Keywords
Breast Cancer, Immunohistochemistry, Tamoxifen, Progression free survival (PFS), p21WAF1
References
Kumar S. .2022 .Hormonal and targeted treatments in breast cancer.". In Breast Cancer: Comprehensive Management, : 443-463.
Ghanavati M. .1806 .Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta‐analysis. ” Cancer Reports, 6(4) : e1806.
Remmel H.L. .2024 ."Comparative analysis of Endoxifen, Tamoxifen and Fulvestrant: A Bioinformatics Approach to Uncover Mechanisms of Action in Breast Cancer. " bioRxiv, : 2024-10.
Falato C. .2022 .Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and her2- negative metastatic breast cancer. ” Cancer Treatment Reviews, 102496 : 102496.
Smolarz B. .2022 .Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). ” Cancers, 14(10) : 2569-0.
Tsai Y.C. .2024 ."Investigating radiation therapy treatments with cell cycle and DNA repair inhibitors in triple-negative breast cancer." Department of Medicine. McGill University, : .
Liao Y. .2023 .Ethyl acetate extract of antenoron filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing skp2/p21 signaling axis. ” Phytomedicine, 154856 : 154856-0.
Shaikh M.A.J. .2024 .Non-coding RNAs: Key regulators of CDK and Wnt/β-catenin signaling in cancer. ” Pathology - Research and Practice, 155659 : 155659-0.
Aung T.M. .2024 .Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis. ” PLOS ONE, 0303337(5) : e0303337-0.
Sun J. .2024 .Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (review. ” International Journal of Oncology, 64(4) : 44-0.
Khallouki F.,April 2023 . .An update on tamoxifen and the chemopreventive potential of vitamin e in breast cancer management. ” Journal of Personalized Medicine, 13(5) : 754-0.
Mir Manzoor,Ahmad Shazia,Sofi M. Sultan,Khan M. Sultan .2023 ."CDk Inhibitor for Treatment of Breast Cancer." In: Therapeutic Potential of Cell Cycle Kinases in Breast Cancer. , : 313-333.
Wiecken W,M. W .2024 .The immune checkpoint lag-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma. ” OncoImmunology, 2430066(1) : 2430066-0.
Vitale S.G. .2024 .Risk of endometrial malignancy in women treated for breast cancer: The BLUSH prediction model - evidence from a comprehensive multicentric retrospective cohort study. ” Climacteric, 2376189(5) : 482-488.
Faleh S. .2023 .Predictors of nodal metastases in early stage her2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery. European Journal of Surgical Oncology, 03(8) : 1411-1416.
Chakravarti N.,April 2024 . .XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways. Scientific Reports, 14(1) : 9305-0.
Morgan J. .2023 .Psychosocial outcomes after varying risk management strategies in women at increased familial breast cancer risk: A mixed methods study of patient and partner outcomes. The Annals of The Royal College of Surgeons of England, 0042(1) : 78-91.
Elfoly M. .2024 .Pd-l1 intrinsically promotes the proliferation of breast cancer cells through the skp2-p27/p21 axis. Cancer Cell International, 24(1) : 161-0.
Yue Y. .2021 .N6-methyladenosine-mediated downregulation of mir-374c-5p promotes cadmium-induced cell proliferation and metastasis by targeting grm3 in breast cancer cells. ” Ecotoxicology and Environmental Safety, 113085 : 113085-0.
Choi S.,November S. .2023 .MicroRNA-606 inhibits the growth and metastasis of triple-negative breast cancer by targeting Stanniocalcin 1. , 8661(1) : .
Nasri E. .2024 .Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.” The Cancer Journal. , 30(3) : 133-139.
Koh Y.W.,November 2024 . .Senescence cell signature associated with poor prognosis, epithelial-mesenchymal transition, solid histology and spread through air spaces in lung adenocarcinoma. GeroScience, 47(2) : 2423-2438.
Huang Y. . .Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer. ” Breast Cancer, 31(5) : 917-925.
Gowdini E.,November 2022 . .DOK7 CpG hypermethylation in blood leukocytes as an epigenetic biomarker for acquired tamoxifen resistant in breast cancer. ” Journal of Human Genetics, 68(1) : 33-38.
Liang X.,April 2022 . .DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer. ” Molecular Biology Reports, 49(5) : 3939-3947.
Tian Y. .2023 .DHMMF, a natural flavonoid from Resina Draconis, inhibits hepatocellular carcinoma progression via inducing apoptosis and G2/M phase arrest mediated by DNA damage-driven upregulation of p21.” Biochemical Pharmacology. , 115518 : 115518-0.
Nasir A. . .p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors. ” Cancer Genomics - Proteomics, 20(2023) : 522-530.
Leelo A.K.,Leelo H.A.K. .2019 .Immunohistochemical expression of TGF-β1 and Ki-67 in a paraffin-embedded section of breast cancer tissue. Indian Journal of Forensic Medicine & Toxicology, 00453(2019) : 0973-9130.
Rajendran S. .2021 .p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes. ” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 188668(1) : 188668-0.
White-Gilbertson S.,April 2024 .2024 .Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization. ” Journal of Biological Chemistry, 107136(4) : 107136-0.
Nakao T. . .Prognostic impact of the combination of p16ink4a, p21 and immunoscore in rectal cancer. International Journal of Clinical Oncology, 29(8) : 1152-1160.
April 2024 . .Low-level expression of p-S6 is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma. International Journal of Molecular Sciences, 25(8) : 4304-0.
Wang Y. .2021 .Improved breast cancer histological grading using deep learning. ” Annals of Oncology, 09(1) : 89-98.
Fei ,Yang ,J. Clin. Pathol. June .2024 .Clinicopathological significance and prognostic analysis of p21 and EGFR in colorectal cancer: A retrospective analysis on 12 319 cases. , : .
Lee D.H.,November 2023 . .CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents. ” Molecular Oncology, 18(1) : 13541-232.
Melo M.L. .2023 .N-acylhydrazone derivative modulates cell cycle regulators promoting mitosis arrest and apoptosis in estrogen positive mcf-7 breast cancer cells. ” Toxicology in Vitro, 105686 : 105686-0.
Margulies B.S. . .Reshaping the landscape of locoregional treatments for breast cancer liver metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in balb/c mice inoculated with 4t1 triple negative breast cancer cells in the liver. ” PLOS One, 0323621(6) : e0323621-0.
Liu R. .2023 .Stnm1 in human cancers: Role, function and potential therapy sensitizer. ” Cellular Signalling, 110775 : 110775-0.
0

Citations

0

Downloads

46

Views